Patents by Inventor Ronggai Sun

Ronggai Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant BCG strains with enhanced ability to escape the endosome
    Patent number: 8043857
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: October 25, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Electroporation of and overexpression of antigens in mycobacteria
    Patent number: 7829104
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: November 9, 2010
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Recombinant BCG Strains with Enhanced Ability to Escape the Endosome
    Publication number: 20100233213
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Application
    Filed: December 31, 2009
    Publication date: September 16, 2010
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Recombinant BCG tuberculosis vaccine designed to elicit immune responses to in all physiological stages of infection and disease
    Patent number: 7670609
    Abstract: A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The vaccine is protective against active Mtb infection both pre- and post-exposure to Mtb, and thus prevents disease symptoms due to the recurrence of a latent Mtb infection.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: March 2, 2010
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Avigdor Shafferman, Anat Zvi, Naomi Ariel, John Fulkerson, Ronggai Sun, Rosemary Chang, Jerald C. Sadoff
  • Recombinant BCG strains with enhanced ability to escape the endosome
    Publication number: 20100047286
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a Histocompatibility-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell. The invention also provides vaccine preparations containing the Mycobacterium strains.
    Type: Application
    Filed: November 23, 2005
    Publication date: February 25, 2010
    Applicant: AERAS GLOBAL TB VACCINE FOUNDATION
    Inventors: Ronggai Sun, David M. Hone, Jerald C. Sadoff
  • Recombinant BCG strains with enhanced ability to escape the endosome
    Patent number: 7666656
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomolytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: February 23, 2010
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Transformed bacterium lacking selectable marker and overexpression of antigens in mycobacteria
    Patent number: 7625572
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: December 1, 2009
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • NOVEL RECOMBINANT BCG TUBERCULOSIS VACCINE DESIGNED TO ELICIT IMMUNE RESPONSES TO MYCOBACTERIUM TUBERCULOSIS IN ALL PHYSIOLOGICAL STAGES OF INFECTION AND DISEASE
    Publication number: 20090136534
    Abstract: A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The vaccine is protective against active Mtb infection both pre- and post-exposure to Mtb, and thus prevents disease symptoms due to the recurrence of a latent Mtb infection.
    Type: Application
    Filed: November 27, 2007
    Publication date: May 28, 2009
    Inventors: Avigdor Shafferman, Anat Zvi, Naomi Ariel, John Fulkerson, Ronggai Sun, Rosemary Chang, Jerald C. Sadoff
  • Electroporation of Mycobacterium and Overexpression of Antigens in Mycobacteria
    Publication number: 20080286852
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Application
    Filed: May 31, 2007
    Publication date: November 20, 2008
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • RECOMBINANT BCG STRAINS WITH ENHANCED ABILITY TO ESCAPE THE ENDOSOME
    Publication number: 20080095794
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomolytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Application
    Filed: May 31, 2007
    Publication date: April 24, 2008
    Inventors: Ronggai Sun, David Hone, Jerald Sadoff
  • Electroporation of mycobacterium and overexpression of antigens in mycobacteria
    Publication number: 20060121054
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Application
    Filed: November 29, 2005
    Publication date: June 8, 2006
    Inventors: Ronggai Sun, David Hone, Jerald Sadoff
  • Recombinant BCG strains with attenuated immunosuppressive properties
    Publication number: 20060115494
    Abstract: Strains of Mycobacterium that have decreased immunosuppressive properties are provided. The Mycobacterium strains are genetically engineered to express but not secrete super-oxide dismutase (Sod). The presence of cytosol bound Sod allows replication and growth of the Mycobacterium, but does not result in attenuation of the host immune response. The Mycobacterium strains provide improved properties for use as vaccines.
    Type: Application
    Filed: November 23, 2005
    Publication date: June 1, 2006
    Inventors: Ronggai Sun, David Hone, Jerald Sadoff